

Phase I Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis

Bonini, Stefano; Lambiase, Alessandro; Rama, Paolo; Filatori, Isabella; Allegretti, Marcello; Chao, Wendy; Mantelli, Flavio; REPARO Study Group; Rauz, Saaeha

DOI:

[10.1016/j.optha.2018.03.004](https://doi.org/10.1016/j.optha.2018.03.004)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Bonini, S, Lambiase, A, Rama, P, Filatori, I, Allegretti, M, Chao, W, Mantelli, F, REPARO Study Group & Rauz, S 2018, 'Phase I Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis', *Ophthalmology*.
<https://doi.org/10.1016/j.optha.2018.03.004>

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Manuscript Details

| | |
|---|--|
| Manuscript number | OPHTHA_2017_2894_R1 |
| Title | Phase I Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis |
| Article type | Case Report |
| Taxonomy | Cornea Ulcers, Ulcerative Keratitis, Biologic Therapy, Neurotrophic Keratopathy |
| Manuscript category | MS to Report (Invited) |
| Corresponding Author | Alessandro Lambiase |
| Corresponding Author's Institution | Sapienza University |
| Order of Authors | Stefano Bonini, Alessandro Lambiase, Paolo Rama, Isabella Filatori, Marcello Allegretti, Wendy Chao, flavio mantelli |

Phase I Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis

Stefano Bonini, MD,¹ Alessandro Lambiase, MD, PhD,² Paolo Rama, MD,³ Isabella Filatori, BSc,⁴ Marcello Allegretti, PhD,⁴ Wendy Chao, PhD,⁴ Flavio Mantelli, MD, PhD,⁴ for the REPARO Study Group*

¹ Ophthalmology Department, Campus Bio-Medico University, Rome, Italy.

² Sense Organs Department, Sapienza University, Rome, Italy.

³ San Raffaele Scientific Institute, Milan, Italy.

⁴ Dompé Farmaceutici SpA, Milan, Italy.

* Members of the REPARO Study Group are listed in Appendix 1

Corresponding author: Alessandro Lambiase, MD, PhD, Sense Organs Department, Sapienza University, Viale del Policlinico 155, Rome, Italy, 00100, Phone: +39 06 49975305, Fax: +39 06 49975306, alessandro.lambiase@uniroma1.it

Meeting Presentation: Portions of this work have been presented at the 2014 Association for Research in Vision and Ophthalmology Annual Meeting, May 4–8, 2014, Orlando, Florida (Abstract 4690).

Conflicts of Interest/Financial Disclosures: The authors have made the following disclosures:

S.B.: Consultant/advisor – Dompé Farmaceutici, SpA.

A.L.: Consultant/advisor – Dompé Farmaceutici, SpA.

24 P.R.: Scientific Advisory Board, Dompé Farmaceutici, SpA.

25 I.F.: Employee – Dompé Farmaceutici SpA.

26 M.A.: Employee – Dompé Farmaceutici, SpA.

27 W.C.: Employee – Dompé Farmaceutici, SpA.

28 F.M.: Employee – Dompé Farmaceutici, SpA.

29

30 **Financial Support:** Supported by Dompé Farmaceutici SpA. The sponsor participated in the
31 design and conduct of the study; data collection for pharmacokinetics and immunogenicity
32 assessments; management, analysis, and interpretation of the data; and preparation and
33 review of the manuscript. The sponsor was not involved in efficacy data collection for
34 masked central analysis.

35 **Trial registration:** ClinicalTrials.gov identifier: NCT01756456

36

37 **Appendix 1:** The REPARO Study Group

38

39 **Principal Investigator:** Stefano Bonini, MD, Ophthalmology Department, Campus Bio-
40 Medico University, Rome, Italy

41 **Investigators:**

42 Alessandro Lambiase, MD – Sense Organs Department, Sapienza University, Rome, Italy;

43 Paolo Rama, MD – San Raffaele Scientific Institute, Milan, Italy;

44 Elisabeth Messmer, MD – Klinikum der Universität München, Germany;

45 Pasquale Aragona, MD – Azienda Ospedaliera University of Messina, Italy;

46 Gerd Geerling, MD – Department of Ophthalmology, Heinrich-Heine-University, Düsseldorf,
47 Germany;
48 Leonardo Mastropasqua, MD – Gabriele D’Annunzio University, Chieti, Italy;
49 Rita Mencucci, MD – Careggi University Hospital, Florence, Italy;
50 John Dart, MD – National Institute of Health Research Biomedical Research Centre,
51 Moorfields Eye Hospital, NHS Foundation Trust, UCL Institute of Ophthalmology, London,
52 United Kingdom;
53 Andrea Leonardi, MD – Department of Neuroscience, Ophthalmology Unit, University of
54 Padua, Italy;
55 Jesus Montero, MD – Cartuja Vision, Sevilla, Spain;
56 Maurizio Rolando, MD – Ophthalmology Department, University of Genoa, Italy;
57 Thomas Reinhard, MD – Universitäts-Augenklinik Freiburg, Germany;
58 Claus Cursiefen, MD – University of Cologne, Cologne, Germany;
59 Jaime Etxebarria, MD – Hospital de Cruces, Vizcaya, Spain;
60 Eric Gabison, MD – Fondation Ophtalmologique Adolphe de Rothschild, & Université Paris
61 Diderot, Paris, France;
62 Jacek P. Szaflik, MD, PhD – Department of Ophthalmology, Medical University of Warsaw,
63 SPKSO Ophthalmic University Hospital, Warsaw, Poland;
64 Nacim Bouheraoua, MD, PhD - Quinze-Vingts National Ophthalmology Hospital, UPMC-
65 Sorbonne Universities, INSERM UMR S 968, Institut de la Vision, CNRS, UMR 7210, Paris,
66 France;
67 Maria De La Paz, MD – Barraquer Eye Center, Barcelona, Spain;
68 Maite Sainz de la Maza, MD – Hospital Clinic de Barcelona, Spain;

69 Edward Wylegala, MD – Medical University of Silesia -District Railway Hospital Katowice
70 Poland;

71 Francisco Figueiredo, MD, PhD – Department of Ophthalmology, Royal Victoria Infirmary
72 and Newcastle University, Newcastle Upon Tyne, United Kingdom;

73 Paolo Fogagnolo, MD – Clinica Oculistica, ASST Santi Paolo e Carlo, Università degli Studi di
74 Milano, Milano, Italy;

75 Parwez Hossain, MD – Southampton General Hospital, University of Southampton, United
76 Kingdom;

77 Katrin Lorenz, MD – Department of Ophthalmology, University Medical Center, Johannes
78 Gutenberg-University Mainz, Germany;

79 Pierre-Yves Robert, MD – CHY Dupuytren, Limoges, France;

80 José Benitez del Castillo, MD – Hospital Clinico San Carlos, Madrid, Spain;

81 Catherine Creuzot-Garcher, MD – Hopital François Mitterrand, CHU Dijon, France;

82 Friedrich Kruse, MD – Universitätsklinikum Erlangen, Germany;

83 François Malecaze, MD – CHU Toulouse-Purpan, Toulouse, France;

84 Jesús Merayo-Llodes, MD – Instituto Universitario Fernández-Vega. University of Oviedo,
85 Spain;

86 Saaeha Rauz, MD – University of Birmingham, United Kingdom;

87 Jorge Alio, MD – Vissum Corporación Oftalmológica de Alicante, Spain;

88 Fiona Carley, MD – Manchester Royal Eye Hospital, Manchester, United Kingdom;

89 Ramaesh Kanna, MD – Hospital of Glasgow, United Kingdom;

90 Carina Koppen, MD – Universitair Ziekenhuis Antwerpen, Edegem, Belgium;

91 Janos Nemeth, MD – Semmelweis University, Budapest, Hungary;

92 Joaquim Neto Murta, MD – University Hospital Coimbra, EPE, Coimbra, Portugal;

93 Luis Torrao, MD – Centro Hospitalar de São João, Porto, Portugal.

94

95 **This article contains additional online-only material. The following should appear online-**
96 **only:**
97 Appendix 1 (REPARO Study Group)
98 Figure S1 (CONSORT diagram)
99 Figure S2 (PK results)
100

Report (998 of 1000 words)

Neurotrophic keratitis/keratopathy (NK), a rare degenerative corneal disease, lacks effective pharmacologic therapies.¹ Because NK pathology involves trigeminal nerve damage and loss of corneal innervation, nerve growth factor (NGF) is surmised to promote healing of NK.² Preliminary studies with murine NGF demonstrated efficacy for treating corneal neurotrophic ulcers³; however, the complex tertiary structure of NGF has complicated the production of recombinant human NGF (rhNGF) suitable for clinical development. To this end, we developed an *E. coli*-derived rhNGF formulation that demonstrated to be well tolerated and safe for topical ophthalmic use in a phase I study in healthy volunteers.⁴ Here, we report phase I results of topical rhNGF for patients with moderate-to-severe NK.

NGF0212/REPARO (Latin, “repair”) was a phase I/II randomized, double-masked, multicenter, vehicle-controlled, parallel group study (ClinicalTrials.gov identifier NCT01756456) that evaluated the safety and efficacy of rhNGF eye drops (10 or 20 µg/ml, 6 drops/day for 8 weeks) in patients with moderate (stage 2) or severe (stage 3) NK.

Patients ≥18 years of age with stage 2/3 NK were enrolled according to published diagnostic criteria and inclusion/exclusion criteria described in the REPARO phase II report.⁵ Table 1 summarizes patient demographics, baseline characteristics, and prior NK treatments.

124
125 Eighteen patients (2 cohorts of 9 consecutively enrolled patients each) with stage 2 or 3 NK
126 gave informed consent and were randomized 7:2 to rhNGF 10 µg/ml vs. vehicle (cohort A)
127 or rhNGF 20 µg/ml vs. vehicle (cohort B). Sample size was based on clinical feasibility (i.e.,
128 no formal power calculation was performed), as phase I aimed primarily to assess the
129 safety and systemic absorption of topical rhNGF to support proceeding with phase II, which
130 was conducted, analyzed, and reported separately.⁵

131
132 Patients, investigators, and site/sponsor staff were masked to primary randomized
133 treatment. Indistinguishable treatment kits were randomly assigned by Statistical Analysis
134 System programmers. A clinical research organization maintained the masked database. No
135 formal statistical testing was applied to phase I data. The study obtained institutional
136 review board and independent ethics committee approval (detailed in the phase II report⁵)
137 and complied with the Declaration of Helsinki, Code of Federal Regulations, and Good
138 Laboratory/Clinical Practice guidelines.

139
140 Figure S1 (available at www.aaojournal.org) depicts overall study design and patient
141 disposition, including reasons for withdrawal. The study included an 8-week controlled
142 treatment period and a 48- or 56-week follow-up (duration determined by treatment
143 allocation and corneal healing status during controlled treatment). In the event of treatment
144 failure during the 8-week controlled treatment period (pre-defined as failure to achieve corneal
145 healing, recurrence of NK after healing, or deterioration as described in the phase II
146 report⁵), vehicle-treated patients were eligible to receive 8 weeks of uncontrolled rhNGF

treatment (cohort A: 10 µg/ml; cohort B: 20 µg/ml) before continuing follow-up (total follow-up: 56 weeks). However, no phase I patients entered the 56-week follow-up period.

The primary safety variable was incidence of adverse events (AEs), defined per GCP guidelines as any untoward medical occurrences in patients who received study treatment, regardless of causal or temporal association. Other safety parameters included visual analogue scale for ocular tolerability (described in the phase II report⁵), best corrected distance visual acuity measured in Early Treatment Diabetic Retinopathy Study (ETDRS) letters, intraocular pressure, dilated fundus ophthalmoscopy, vital signs, hematology, and clinical chemistry.

Table 1 summarizes treatment-related AEs (TAEs), defined as AEs recorded by the investigator as having possible, probable, or highly probable relationships to study treatment, during controlled treatment. Eye pain and headache were the most frequently reported TAEs during controlled treatment, each occurring in 2 patients (28.6%) in the rhNGF 20 µg/ml group. TAEs reported during controlled treatment occurred in 1 of 18 patients each. No TAEs were reported during the 48-week follow-up. No deaths occurred controlled treatment or follow-up, nor were there any notable trends or clinically significant differences over time or between treatment groups in laboratory parameters, vital signs, or other ocular safety assessments.

Pharmacokinetics (PK) profiling was performed as described previously.⁴ As shown in Figure S2 (available at www.aaojournal.org), only two patients had detectable serum NGF

at any time point. Of note, the patient in rhNGF 10 µg/ml group only had one positive NGF measurement during the study, and the patient in the rhNGF 20 µg/ml group had detectable serum NGF levels at all time points, even prior to initiating study treatment. Taken together, the PK results suggest individual fluctuations of endogenous NGF independent of study treatment.

Although the phase I study was not designed or powered for efficacy outcomes, corneal healing (<0.5 mm fluorescein staining in the lesion area) was assessed in clinical pictures by central readers (masked to treatment assignment and duration) at week 4 (primary endpoint) and week 8 (key secondary endpoint). At week 4, based on post-baseline last-observation-carried-forward analysis, corneal healing was achieved by 1/4 patients (25.0%) receiving vehicle, 3/7 patients (42.9%) receiving rhNGF 10 µg/ml, and 3/7 patients (42.9%) receiving rhNGF 20 µg/ml. Of patients with responses available at week 8, corneal healing was achieved by 1/2 patients (50%) receiving vehicle, 4/6 patients (66.7%) receiving rhNGF 10 µg/ml, and 6/7 patients (85.7%) receiving rhNGF 20 µg/ml. No phase I patients discontinued due to a lack of efficacy or inadequate control of NK. Prior to week 8, no patients in any treatment group experienced deterioration. At week 8, 1 patient who received rhNGF 20 µg/ml experienced a decrease in BCDVA score of >5 ETDRS letters.

The REPARO phase I study demonstrated that topical ophthalmic rhNGF (10 or 20 µg/ml), administered 6 drops/day for 8 weeks, was well tolerated in patients with stage 2/3 NK. No safety concerns arose; most AEs were ocular, mild, transient, and did not require

193 discontinuing or corrective treatments. Most patients had undetectable serum NGF, and
194 systemic AEs were infrequent and mild. This is consistent with previous PK findings in
195 healthy volunteers⁴ and lack of detectable systemic NGF or immunogenicity in the phase II
196 study.⁵ Taken together, these results suggest unlikely systemic absorption or accumulation
197 of rhNGF. Favorable trends in corneal healing suggest that topical ophthalmic rhNGF may
198 be effective for treating patients with moderate-to-severe NK.

REFERENCES

1. Mastropasqua L, Massaro-Giordano G, Nubile M, Sacchetti M. Understanding the Pathogenesis of Neurotrophic Keratitis: The Role of Corneal Nerves. *J Cell Physiol* 2016.
2. Lambiase A, Mantelli F, Sacchetti M, et al. Clinical applications of NGF in ocular diseases. *Arch Ital Biol* 2011;149(2):283-92.
3. Lambiase A, Rama P, Bonini S, et al. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. *N Engl J Med* 1998;338(17):1174-80.
4. Ferrari MP, Mantelli F, Sacchetti M, et al. Safety and pharmacokinetics of escalating doses of human recombinant nerve growth factor eye drops in a double-masked, randomized clinical trial. *BioDrugs* 2014;28(3):275-83.
5. Bonini S, Lambiase A, Rama P, et al. Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. *Ophthalmology* 201X;XX(X):XX-XX.

Table 1. Patient demographics, baseline characteristics, prior treatments, and treatment-related adverse events* (controlled treatment period).

| Characteristics | rhNGF 10 µg/ml (N=7) | | rhNGF 20 µg/ml (N=7) | | Vehicle (N=4) | |
|---|-------------------------|-----------------|-------------------------|-----------------|------------------|-----------------|
| Age (years) | | | | | | |
| Mean (SD) | 61.7 (21.47) | | 52.0 (17.24) | | 64.3 (24.06) | |
| Median (min, max) | 67.0 (29, 80) | | 55.0 (24, 71) | | 68.5 (34, 86) | |
| Female, n (%) | 3 (42.9) | | 4 (57.1) | | 2 (50.0) | |
| Ethnicity, n (%) | | | | | | |
| Hispanic, Latino, or Spanish | 1 (14.3) | | 0 | | 0 | |
| N/A | 0 | | 1 (14.3) | | 0 | |
| Race, n (%) | | | | | | |
| White | 7 (100.0) | | 6 (85.7) | | 4 (100.0) | |
| N/A | 0 | | 1 (14.3) | | 0 | |
| Primary NK diagnosis, n (%) | | | | | | |
| Stage 2 | 3 (42.9) | | 5 (71.4) | | 2 (50.0) | |
| Stage 3 | 4 (57.1) | | 2 (28.6) | | 2 (50.0) | |
| Underlying etiology, n (%) | | | | | | |
| Diabetes mellitus | 1 (14.3) | | 2 (28.6) | | 1 (25.0) | |
| Dry eye disease | 1 (14.3) | | 0 | | 0 | |
| Herpetic eye disease* | 1 (14.3) | | 2 (28.6) | | 2 (50.0) | |
| Neurosurgical procedure (medulloblastoma excision) | 2 (28.6) | | 1 (14.3) | | 0 | |
| Ocular surgery or procedure | | | | | | |
| Cataract surgery/scleral buckle/vitrectomy | 1 (14.3) | | 1 (14.3) | | 0 | |
| Keratoplasty | 1 (14.3) | | 0 | | 0 | |
| LASIK | 0 | | 1 (14.3) | | 0 | |
| Stroke | 0 | | 0 | | 1 (25.0) | |
| Prior treatments, n (%)† | | | | | | |
| Artificial tears/gels/ointments | 1 (14.3) | | 6 (85.7) | | 3 (75.0) | |
| Preservative free artificial tears/gels/ointments | 4 (57.1) | | 4 (57.1) | | 2 (50.0) | |
| Topical antibiotics | 4 (57.1) | | 4 (57.1) | | 3 (75.0) | |
| Therapeutic contact lens | 2 (28.6) | | 1 (14.3) | | 1 (25.0) | |
| Autologous serum eye drops | 1 (14.3) | | 2 (28.6) | | 1 (25.0) | |
| Other | 0 | | 2 (28.6) | | 0 | |
| Treatment-related Adverse Events | N' | n | N' | n | N' | n |
| Body system | | | | | | |
| MedDRA preferred term | | | | | | |
| Any adverse event | 4 | 1 (14.3) | 12 | 3 (42.9) | 1 | 1 (25.0) |
| Eye disorders | 3 | 1 (14.3) | 5 | 3 (42.9) | 1 | 1 (25.0) |
| Eye pain | 0 | 0 | 2 | 2 (28.6) | 0 | 0 |
| Conjunctival hyperemia | 2 | 1 (14.3) | 0 | 0 | 0 | 0 |
| Erythema of eyelid | 1 | 1 (14.3) | 0 | 0 | 0 | 0 |
| Eye inflammation | 0 | 0 | 1 | 1 (14.3) | 0 | 0 |
| Eye irritation | 0 | 0 | 1 | 1 (14.3) | 0 | 0 |
| Foreign body sensation in eyes | 0 | 0 | 0 | 0 | 1 | 1 (25.0) |
| Photophobia | 0 | 0 | 1 | 1 (14.3) | 0 | 0 |
| General disorders and administration site conditions | 1 | 1 (14.3) | 3 | 2 (28.6) | 0 | 0 |
| Disease progression‡ | 1 | 1 (14.3) | 0 | 0 | 0 | 0 |
| Fatigue | 0 | 0 | 1 | 1 (14.3) | 0 | 0 |
| Instillation site pruritus | 0 | 0 | 1 | 1 (14.3) | 0 | 0 |
| Irritability | 0 | 0 | 1 | 1 (14.3) | 0 | 0 |
| Nervous system disorders | 0 | 0 | 2 | 2 (28.6) | 0 | 0 |

| | | | | | | |
|--|----------|----------|----------|-----------------|----------|----------|
| Headache | 0 | 0 | 2 | 2 (28.6) | 0 | 0 |
| Cardiac disorders | 0 | 0 | 1 | 1 (14.3) | 0 | 0 |
| Cardiovascular disorder§ | 0 | 0 | 1 | 1 (14.3) | 0 | 0 |
| Musculoskeletal and connective tissue disorders | 0 | 0 | 1 | 1 (14.3) | 0 | 0 |
| Muscle spasms | 0 | 0 | 1 | 1 (14.3) | 0 | 0 |

Abbreviations: MedDRA = Medical Dictionary for Regulatory Activities; min = minimum; max = maximum; N/A: not available (ethnicity and race were not collected in all countries); N = number of patients randomized to each treatment group at baseline; n = number of patients in each category; N' = number of adverse events reported, n' = number of patients reporting the adverse event; rhNGF = recombinant human nerve growth factor; SD = standard deviation.

Percentages (%) are calculated using the number randomized to each treatment group (N) as the denominator.

*Treatment-related adverse events are those events recorded by the investigator as having a possible, probable, or highly probable relationship to study treatment.

†Includes herpes simplex, herpes zoster, and recurrent herpetic keratitis

‡Patients may have received more than one prior treatment

§Disease progression was defined as increase in lesion size ≥ 1 mm; decrease in best corrected distance visual acuity (BCDVA) by >5 Early Treatment Diabetic Retinopathy Study (ETDRS) letters; progression in lesion depth to corneal melting or perforation; or onset of infection. One patient in the rhNGF 10 μ g/ml group had ≥ 1 mm increase in lesion size from baseline. One patient had a transient decrease in blood pressure from baseline

Appendix 1. REPARO Study Group and Administration

STUDY INVESTIGATORS

The following principal investigators were members of the REPARO Study Group:

Stefano Bonini, MD, Ophthalmology Department Campus Bio-Medico University, Rome, Italy

Alessandro Lambiase, MD, PhD, Sense Organs Department, Sapienza University, Rome, Italy

Paolo Rama, MD, San Raffaele Scientific Institute, Milan, Italy

Elisabeth Messmer, MD, Klinikum der Universität München, Germany

Pasquale Aragona, MD, Azienda Ospedaliera University of Messina, Italy

Gerd Geerling, MD, Department of Ophthalmology, Heinrich-Heine-University, Düsseldorf, Germany

Leonardo Mastropasqua, MD, Gabriele D'Annunzio University, Chieti, Italy

Rita Mencucci, MD, Careggi University Hospital, Florence, Italy

John Dart, MD, National Institute of Health Research Biomedical Research Centre, Moorfields Eye Hospital, NHS Foundation Trust, UCL Institute of Ophthalmology, London, United Kingdom

Andrea Leonardi, MD, Department of Neuroscience, Ophthalmology Unit, University of Padua, Italy

Jesus Montero, MD, Cartuja Vision, Sevilla, Spain

Maurizio Rolando, MD, Ophthalmology Department, University of Genoa, Italy

Thomas Reinhard, MD, Universitäts-Augenklinik Freiburg, Germany

Claus Cursiefen, MD, University of Cologne, Cologne, Germany

Jaime Etxebarria, MD, Hospital de Cruces, Vizcaya, Spain

Eric Gabison, MD, Fondation Ophtalmologique Adolphe de Rothschild, & Université Paris Diderot, Paris, France

Jacek P. Szaflik, MD, PhD, Department of Ophthalmology, Medical University of Warsaw, SPKSO Ophthalmic University Hospital, Warsaw

Vincent Borderie, MD, Centre Hospitalier National d'Ophtalmologie, Paris, France

Maria De La Paz, MD, Barraquer Eye Center, Barcelona, Spain

Maite Sainz de la Maza, MD, Hospital Clinic de Barcelona, Spain

Edward Wylegala, MD, Medical University of Silesia -District Railway Hospital, Katowice, Poland

Francisco Figueiredo, MD, PhD, Department of Ophthalmology, Royal Victoria Infirmary and Newcastle University, Newcastle Upon Tyne, United Kingdom

Paolo Fogagnolo, MD, Clinica Oculistica, ASST Santi Paolo e Carlo, Università degli Studi di Milano, Milano, Italy

Parwez Hossain, MD, Southampton General Hospital, University of Southampton, United Kingdom

Katrin Lorenz, MD, Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University Mainz, Germany

Pierre-Yves Robert, MD, CHY Dupuytren, Limoges, France

José Benitez del Castillo, MD, Hospital Clinico San Carlos, Madrid, Spain

Catherine Creuzot-Garcher, MD, Hopital François Mitterrand, CHU Dijon, France

Friedrich Kruse, MD, Universitätsklinikum Erlangen, Germany

François Malecaze, MD, CHU Toulouse-Purpan, Toulouse, France

Jesús Merayo-Llodes, MD, Instituto Universitario Fernández-Vega. University of Oviedo, Spain

Saaeha Rauz, MD, University of Birmingham, United Kingdom

Jorge Alio, MD, Vissum Corporación Oftalmológica de Alicante, Spain

Fiona Carley, MD, Manchester Royal Eye Hospital, Manchester, United Kingdom

Ramaesh Kanna, MD, Hospital of Glasgow, United Kingdom

Carina Koppen, MD, Universitair Ziekenhuis Antwerpen, Edegem, Belgium

Janos Nemeth, MD, Semmelweis University, Budapest, Hungary

Joaquim Neto Murta, MD, University Hospital Coimbra, EPE, Coimbra, Portugal

Luis Torrao, MD, Centro Hospitalar de São João, Porto, Portugal

STUDY ADMINISTRATION

Reparo Clinical Trial Manager

Isabella Filatori, Clinical Development Manager, Dompé farmaceutici S.p.A

Sponsor staff (Dompé farmaceutici S.p.A.)

Marcello Allegretti, PhD, Chief Scientific Officer

Flavio Mantelli, MD, PhD, Chief Medical Officer

Francesco Sinigaglia, MD, Ophthalmology Consultant

Laura Boga, Senior Safety Manager-Drug Safety

Wendy Chao, PhD, Associate Director, Ophthalmology Clinical Development

Paolo Battigello, Clinical Development Specialist

Valentina Vaja, PhD, Clinical Development Specialist

Franca Cattani, Biotech – Process and Analytical Development Laboratory

Contract research organization (CRO) staff (inVentiv Health Clinical)

Andy Cross, Director Biostatistics

Kelly Sharp, Senior Statistician

Ed Richards, Project Director

Ludovic Couillard, Associate Project Director

Ally Gasco, Principal Medical Writer

Deepa Khadar, Senior Medical Writer

Central imaging (University Hospital of Cologne)

Felix Bock, PhD, Laboratory Leader, Coric Cornea Lab, Experimental Ophthalmology

Immunology (Harlan Laboratories Ltd.)

Denise Dickel, MSc, Head of Bioanalytics and Mechanistic Toxicology Contract Research Services

Early Treatment Diabetic Retinopathy Study (ETDRS) Chart Training (CertifEYED Associates)

Katherine Burke

Independent Ethics Committees (IECs)

Belgium

Ethisch Comité
UZA
Prof. Dr. Cras, President
Wilrijkstraat 10
2650 Edegem, Belgium

France

Mr. Boffa
CPP (EC) Ile de France V
Saint Antoine Hospital
184, rue du Faubourg Saint-Antoine
75012 Paris, France

Germany

Ethics committee of the Friedrich-Alexander-University
Erlangen-Nürnberg Krankenhausstraße
91054 Erlangen, Germany

Hungary

EGÉSZSÉGÜGYI
TUDOMÁNYOS TANÁCS
KLINIKAI FARMAKOLÓGIAI
ETIKAI BIZOTTSÁGA
1051 Budapest, Arany János utca 6-8. Hungary

Italy

Comitato Etico Coordinatore
COMITATO ETICO dell'IRCCS
OSPEDALE SAN RAFFAELE di MILANO
Via Olgettina, 60
20132 MILANO, Italia

Poland

Komisja Bioetyczna przy Uniwersytecie Medycznym w Warszawie
Ul: Żwirki i Wigury
02-091 Warszawa, Poland

Portugal

CEIC – Parque de Saude de Lisboa
Parque de Saude de Lisboa Av.do Brasil, 53 – Pav.17-A
Lisboa, Portugal

Spain

CEIC – Hospital Clinico San Carlos
Doctor Martin Lagos s/n
Madrid 28040
Spain

United Kingdom

NRES Committee – London – City and East South West REC Centre
Level 3, Block B
Whitefriars
Lewins Mead Bristol
BS1 2NT
United Kingdom

| | | | | | | | |
|--|--|---|--|---|--|---|--|
| <p>Ineligible (N=12)</p> | | <p>Assessed for eligibility (N=186)</p> | | <p>Phase II (N=156)</p> | | <p>Treatment failure during controlled vehicle treatment* (N=0)</p> | |
| <p>Phase I (N=18)</p> | | | | | | <p>Allocated at week 8 / entered 56-week follow-up (N=0)</p> | |
| <p>Allocated to cohort A and randomized 7:2 (N=9)</p> | | <p>Allocated to cohort B and randomized 7:2 (N=9)</p> | | <p>rhNGF 10 µg/ml: cohort A (N=0)</p> | | <p>rhNGF 20µg/ml: cohort B (N=0)</p> | |
| <p>rhNGF 10 µg/ml (N=2)</p> <ul style="list-style-type: none"> Received controlled treatment (n=2) Withdrawn on or before week 8 (n=1) <ul style="list-style-type: none"> Adverse event (n=0) Other (n=1) Completed 8 weeks of controlled treatment (n=1) | | <p>Vehicle control (N=2)</p> <ul style="list-style-type: none"> Received controlled treatment (n=2) Withdrawn on or before week 8 (n=1) <ul style="list-style-type: none"> Adverse event (n=0) Other (n=1) Completed 8 weeks of controlled treatment (n=1) | | <p>rhNGF 20µg/ml (N=7)</p> <ul style="list-style-type: none"> Received controlled treatment (n=7) Withdrawn on or before week 8 (n=1) <ul style="list-style-type: none"> Adverse event (n=0) Other (n=1) Completed 8 weeks of controlled treatment (n=7) | | <p>Vehicle control (N=2)</p> <ul style="list-style-type: none"> Received controlled treatment (n=2) Withdrawn on or before week 8 (n=1) <ul style="list-style-type: none"> Adverse event (n=0) Other (n=1) Completed 8 weeks of controlled treatment (n=1) | |
| <p>Entered 48-week follow-up (N=1)</p> <ul style="list-style-type: none"> Withdrawn during follow-up period (n=1) <ul style="list-style-type: none"> Adverse event (n=0) Lost to follow-up (n=1) Other (n=0) Completed 48 weeks of follow-up (n=0) | | <p>Entered 48-week follow-up (N=6)</p> <ul style="list-style-type: none"> Withdrawn during follow-up period (n=1) <ul style="list-style-type: none"> Adverse event (n=0) Lost to follow-up (n=0) Other (n=1) Completed 48 weeks of follow-up (n=5) | | <p>Entered 48-week follow-up (N=1)</p> <ul style="list-style-type: none"> Withdrawn during follow-up period (n=0) <ul style="list-style-type: none"> Adverse event (n=0) Lost to follow-up (n=0) Other (n=0) Completed 48 weeks of follow-up (n=1) | | <p>Continued follow-up (N=0)</p> <ul style="list-style-type: none"> Withdrawn during follow-up period (n=0) <ul style="list-style-type: none"> Adverse event (n=0) Lost to follow-up (n=0) Other (n=0) Completed 56 weeks of follow-up (n=0) | |
| <p>Analysis population (N=2)</p> <ul style="list-style-type: none"> Intention-to-treat (n=2) Safety (n=2) | | <p>Analysis population (N=7)</p> <ul style="list-style-type: none"> Intention-to-treat (n=7) Safety (n=7) | | <p>Analysis population (N=2)</p> <ul style="list-style-type: none"> Intention-to-treat (n=2) Safety (n=2) | | <p>Analysis population (N=0)</p> <ul style="list-style-type: none"> Intention-to-treat (n=0) Safety (n=0) | |

The REPARO phase I study evaluated the safety of topical ophthalmic recombinant human nerve growth factor (rhNGF), 6 drops daily for 8 weeks, in 18 patients (two cohorts of 9 consecutively enrolled patients) with neurotrophic keratitis of severity stage 2 (persistent epithelial defect) or stage 3 (corneal ulcer). Enrollment of cohort A (randomized 7:2 to 10 µg/ml rhNGF or vehicle) preceded enrollment of cohort B (randomized 7:2 to 20 µg/ml rhNGF or vehicle). Patients received 8 weeks of controlled treatment and 48 weeks of follow-up. A 56-week follow-up period was intended for vehicle-treated patients who experienced treatment failure (see text for details), and was to include an additional 8 weeks of uncontrolled treatment with 10 µg/ml rhNGF (cohort A) or 20 µg/ml rhNGF (cohort B) before continuing follow-up for 48 weeks. No patients from the phase I study entered the 56-week follow-up.

Figure S2. REPARO Phase I Pharmacokinetics.

Serum concentration of nerve growth factor (NGF) plotted over time for individual patients in the REPARO Phase I study. Blood samples were taken from patients receiving recombinant human NGF (rhNGF) or vehicle for pharmacokinetics (PK) profiling at various time points over the 8-week controlled treatment period (on days 1, 2; weeks 1, 2, 3, 4, 6; day 55; and week 8). Multiple time points (ranging from 0.5 hours pre-dose to 8 hours post-dose) were taken on days at the beginning and end of the controlled treatment period. For the purpose of these plots, measurements below the lower limit of quantification (LLQ) of 32.000 pg/ml were considered as 0 pg/ml, and only patients with measurements >LLQ are shown. In the rhNGF 10 µg/ml group (n=7, ●), one patient had a serum NGF concentration of 130.868 pg/ml (0.5 hours post dose) on day 1, then <LLQ at all other time points tested. In the rhNGF 20 µg/ml group (n=7, ◇), one patient had serum NGF concentrations >LLQ at all time points, even prior to treatment initiation (893.53 pg/ml 0.5 hours pre-dose on day 1) and ranging from 247.7 pg/ml (week 1) to 1010.7 pg/ml (week 3) during the 8-week controlled treatment period. In the vehicle group (n=4, not shown), no patients had detectable serum NGF at any time point tested.

